New 52 Week Low Today

My Portfolio

Alnylam Pharmaceuticals Inc ALNY:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 06/03/26 EDT

302.50

+9.92 (+3.39%)

Volume

43,926

292.58

+6.46 (+2.26%)

Volume

944,120

52 week range

283.10 - 495.55

Open284.48
Day High293.16
Day Low283.10
Prev Close286.12
52 Week High495.55
52 Week High Date10/20/25
52 Week Low283.10
52 Week Low Date06/03/26

Latest On Alnylam Pharmaceuticals Inc

This year's biotech laggards primed for 2026 recovery: Goldman Sachs' RichterDecember 19, 2025CNBC.com
These stocks could be added to the S&P 500 when benchmark reshuffles this monthDecember 3, 2025CNBC.com
These Best Stocks like Carvana have been on a tear — What to do nowSeptember 8, 2025CNBC.com
Goldman adds Walmart to September ‘conviction list.’ Here’s who else made itSeptember 2, 2025CNBC.com
Best Stocks: Rounding out our biotech exposure with a big winner, one we missedAugust 18, 2025CNBC.com
Best Stocks: Three healthcare names to ponder including a rallying biotechJune 9, 2025CNBC.com

Key Stats

Market Cap39.063B
Shares Out133.51M
10 Day Average Volume0.97M
Dividend-
Dividend Yield-
Beta0.27

Latest On Alnylam Pharmaceuticals Inc

This year's biotech laggards primed for 2026 recovery: Goldman Sachs' RichterDecember 19, 2025CNBC.com
These stocks could be added to the S&P 500 when benchmark reshuffles this monthDecember 3, 2025CNBC.com
These Best Stocks like Carvana have been on a tear — What to do nowSeptember 8, 2025CNBC.com
Goldman adds Walmart to September ‘conviction list.’ Here’s who else made itSeptember 2, 2025CNBC.com
Best Stocks: Rounding out our biotech exposure with a big winner, one we missedAugust 18, 2025CNBC.com
Best Stocks: Three healthcare names to ponder including a rallying biotechJune 9, 2025CNBC.com

KEY STATS

Open284.48
Day High293.16
Day Low283.10
Prev Close286.12
52 Week High495.55
52 Week High Date10/20/25
52 Week Low283.10
52 Week Low Date06/03/26
Market Cap39.063B
Shares Out133.51M
10 Day Average Volume0.97M
Dividend-
Dividend Yield-
Beta0.27

RATIOS/PROFITABILITY

EPS (TTM)4.20
P/E (TTM)69.69
Fwd P/E (NTM)35.35
EBITDA (TTM)806.943M
ROE (TTM)96.94%
Revenue (TTM)4.287B
Gross Margin (TTM)80.83%
Net Margin (TTM)13.46%
Debt To Equity (MRQ)251.68%

EVENTS

Earnings Date07/29/2026(est)
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Content From Our Affiliates

Alnylam, Inceptive form strategic AI collaboration9 Hours AgoTipRanks
Alnylam Shareholders Reaffirm Board, Pay Practices and AuditorMay 27, 2026TipRanks
Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), Insulet (PODD)May 27, 2026TipRanks
J.P. Morgan Reaffirms Their Buy Rating on Alnylam Pharma (ALNY)May 20, 2026TipRanks
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst callsMay 19, 2026TipRanks

Profile

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in...

Amy Schulman J.D.

Independent Chairman of the Board

Yvonne Greenstreet M.D.

Chief Executive Officer, Director

Jeffrey Poulton

Chief Financial Officer, Executive Vice President

Pushkal Garg M.D.

Executive Vice President, Chief Research and Development Officer

Tolga Tanguler

Executive Vice President, Chief Commercial Officer

Address

675 W Kendall St

Cambridge, MA

02142-1168

United States

https://www.alnylam.com/